Literature DB >> 10066353

The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening.

F Loeve1, R Boer, G J van Oortmarssen, M van Ballegooijen, J D Habbema.   

Abstract

A general model for evaluation of colorectal cancer screening has been implemented in the microsimulation program MISCAN-COLON. A large number of fictitious individual life histories are simulated in each of which several colorectal lesions can emerge. Next, screening for colorectal cancer is simulated, which will change some of the life histories. The demographic characteristics, the epidemiology and natural history of the disease, and the characteristics of screening are defined in the input. All kinds of assumptions on the natural history of colorectal cancer and screening and surveillance strategies can easily be incorporated in the model. MISCAN-COLON gives detailed output of incidence, prevalence and mortality, and the results and effects of screening. It can be used to test hypotheses about the natural history of colorectal cancer, such as the duration of progressive adenomas, and screening characteristics, such as sensitivity of tests, against empirical data. In decision making about screening, the model can be used for evaluation of screening policies, and for choosing between competing policies by comparing their simulated incremental costs and effectiveness outcomes. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10066353     DOI: 10.1006/cbmr.1998.1498

Source DB:  PubMed          Journal:  Comput Biomed Res        ISSN: 0010-4809


  69 in total

1.  Probability model for estimating colorectal polyp progression rates.

Authors:  Chaitra Gopalappa; Selen Aydogan-Cremaschi; Tapas K Das; Seza Orcun
Journal:  Health Care Manag Sci       Date:  2010-10-05

2.  Cancer: CRC screening--cost effectiveness of fecal immunochemical tests.

Authors:  Celia Berchi; Guy Launoy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-12-05       Impact factor: 46.802

3.  Computational modeling and multilevel cancer control interventions.

Authors:  Joseph P Morrissey; Kristen Hassmiller Lich; Rebecca Anhang Price; Jeanne Mandelblatt
Journal:  J Natl Cancer Inst Monogr       Date:  2012-05

4.  The impact of stratifying by family history in colorectal cancer screening programs.

Authors:  Simon Lucas Goede; Linda Rabeneck; Iris Lansdorp-Vogelaar; Ann G Zauber; Lawrence F Paszat; Jeffrey S Hoch; Jean H E Yong; Frank van Hees; Jill Tinmouth; Marjolein van Ballegooijen
Journal:  Int J Cancer       Date:  2015-02-20       Impact factor: 7.396

5.  Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia.

Authors:  Alison Brenner; Kirsten Howard; Carmen Lewis; Stacey Sheridan; Trisha Crutchfield; Sarah Hawley; Dan Reuland; Christine Kistler; Michael Pignone
Journal:  J Gen Intern Med       Date:  2013-11-23       Impact factor: 5.128

6.  Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations.

Authors:  David J Vanness; Amy B Knudsen; Iris Lansdorp-Vogelaar; Carolyn M Rutter; Ilana F Gareen; Benjamin A Herman; Karen M Kuntz; Ann G Zauber; Marjolein van Ballegooijen; Eric J Feuer; Mei-Hsiu Chen; C Daniel Johnson
Journal:  Radiology       Date:  2011-08-03       Impact factor: 11.105

7.  State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences.

Authors:  Iris Lansdorp-Vogelaar; S Lucas Goede; Jiemin Ma; Wu Xiau-Cheng; Karen Pawlish; Marjolein van Ballegooijen; Ahmedin Jemal
Journal:  Cancer       Date:  2015-07-06       Impact factor: 6.860

Review 8.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 9.  Colorectal cancer surveillance: what's new and what's next.

Authors:  Johnie Rose; Knut Magne Augestad; Gregory S Cooper
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

10.  Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

Authors:  Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Ann G Zauber; J Dik F Habbema; Ernst J Kuipers
Journal:  J Natl Cancer Inst       Date:  2009-09-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.